妊娠中のスタチンの使用と先天性欠陥のリスク:ノルウェー全国の研究
Jacob J Christensen1, Kirsten B Holven1,2, Martin P Bogsrud3
1Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O. Box 1046 Blindern, Oslo 0317, Norway.
European heart journal
|August 21, 2025
まとめ
この研究では,妊娠中のスタチンまたは脂質調節剤 (LMA) 曝露と先天性異常との間に有意な関連性が見つかりませんでした. これらの薬は胎児の発達に 危険性があることを示唆しています
科学分野:
- 生殖 健康
- 心血管薬学
- テラトロジー
背景:
- スタチンとLMAは,安全性の懸念から,妊娠中に伝統的に禁忌です.
- スタチンとLMAに対する子宮内被曝のリスクに関するデータは限られている.
- 母親のLMA使用と胎児のアウトカムとの間の関連を明確にする必要があります.
研究 の 目的:
- スタチンとLMAの接触と先天性異常との関連を調べる.
- 2022年のメタ解析を最新の研究データで更新します.
- 妊娠中にスタチンとLMAの被曝のリスクを評価する.
主な方法:
- 妊娠中の女性のノルウェーの国家登録データ (2005年−2018年) を利用した.
- 関連性を評価するために混合効果のロジスティック回帰を用いた.
- 逆変数とランダム効果モデルを用いたメタ分析を実施した.
主要な成果:
- スタチンの曝露と,重大または軽微な不形成との間に有意な関連性はありません.
- LMA曝露で心異常のリスクは増加していない.
- 更新されたメタアナリシスでは,重症または心不全のリスクの増加は認められなかった (OR1. 06および1. 24).
結論:
- この大規模な研究とメタアナリシスでは,最初の3ヶ月間のスタチン/LMA暴露と先天性異常との間に有意な関連性が見つかりませんでした.
- 発見は,母親のスタチンの使用と先天性欠陥の間の強いまたは独立したリンクをサポートしません.
- 弱い関連は完全に排除できないが,現在の証拠は安全性を示唆している.
関連する概念動画
Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
Mitral Valve Prolapse III: Nursing Management
36
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
36
Adrenergic Antagonists: ɑ and β-Receptor Blockers
598
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
598
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
430
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
430
Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21


